BR112013033919B1 - Uso de um anticorpo específico para cd19 - Google Patents

Uso de um anticorpo específico para cd19 Download PDF

Info

Publication number
BR112013033919B1
BR112013033919B1 BR112013033919-5A BR112013033919A BR112013033919B1 BR 112013033919 B1 BR112013033919 B1 BR 112013033919B1 BR 112013033919 A BR112013033919 A BR 112013033919A BR 112013033919 B1 BR112013033919 B1 BR 112013033919B1
Authority
BR
Brazil
Prior art keywords
lymphoma
use according
hodgkin
bendamustine
combination
Prior art date
Application number
BR112013033919-5A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013033919A2 (pt
Inventor
Jutta Amersdorffer
Stefan Steidl
Mark Winderlich
Susanne Krohn
Lisa Rojkjaer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of BR112013033919A2 publication Critical patent/BR112013033919A2/pt
Publication of BR112013033919B1 publication Critical patent/BR112013033919B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112013033919-5A 2011-08-16 2012-08-14 Uso de um anticorpo específico para cd19 BR112013033919B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161523861P 2011-08-16 2011-08-16
EP11177658 2011-08-16
EP11177658.9 2011-08-16
US61/523,861 2011-08-16
US201261647539P 2012-05-16 2012-05-16
US61/647,539 2012-05-16
US201261654097P 2012-06-01 2012-06-01
US61/654,097 2012-06-01
PCT/EP2012/065906 WO2013024097A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Publications (2)

Publication Number Publication Date
BR112013033919A2 BR112013033919A2 (pt) 2017-12-19
BR112013033919B1 true BR112013033919B1 (pt) 2022-11-16

Family

ID=47714801

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013033919-5A BR112013033919B1 (pt) 2011-08-16 2012-08-14 Uso de um anticorpo específico para cd19

Country Status (24)

Country Link
US (3) US20140255427A1 (enExample)
EP (2) EP2744515B1 (enExample)
JP (1) JP6184952B2 (enExample)
KR (3) KR20200058583A (enExample)
CN (1) CN103732252B (enExample)
AU (1) AU2012296907B2 (enExample)
BR (1) BR112013033919B1 (enExample)
CA (2) CA2841875C (enExample)
CY (1) CY1125122T1 (enExample)
DK (1) DK2744515T3 (enExample)
ES (1) ES2909722T3 (enExample)
HR (1) HRP20220228T1 (enExample)
HU (1) HUE058350T2 (enExample)
IL (1) IL230293B (enExample)
LT (1) LT2744515T (enExample)
MX (1) MX354479B (enExample)
PL (1) PL2744515T3 (enExample)
PT (1) PT2744515T (enExample)
RS (1) RS63238B1 (enExample)
RU (1) RU2625222C2 (enExample)
SG (1) SG10201606785UA (enExample)
SI (1) SI2744515T1 (enExample)
SM (1) SMT202200159T1 (enExample)
WO (1) WO2013024097A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015277516A1 (en) * 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
PL3302550T3 (pl) * 2015-05-26 2020-02-28 Morphosys Ag Kombinacja przeciwciała anty-cd19 i inhibitora kinazy tyrozynowej brutona i jej zastosowania
SI3337506T1 (sl) 2015-08-21 2021-12-31 Morphosys Ag Kombinacije in njihove uporabe
JP7208010B2 (ja) 2016-03-29 2023-01-18 ユニバーシティ オブ サザン カリフォルニア 癌を標的とするキメラ抗原受容体
SG11201810159TA (en) * 2016-05-30 2018-12-28 Morphosys Ag Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
WO2018102795A2 (en) 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
IL270855B2 (en) 2017-05-31 2023-03-01 Morphosys Ag A therapeutic paradigm for anti-cd19 anti-CD19 antibody combination therapy and Ventoclax
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
IL313736A (en) * 2021-12-22 2024-08-01 Incyte Corp Treatment paradigm for CD19 antibody therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
DK1071752T3 (da) * 1998-04-21 2003-10-20 Micromet Ag CD19xCD3-specifikke polypeptider og anvendelsen deraf
HK1043312B (en) * 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1814544A4 (en) 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
AU2006262232A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. CD19 antibodies and their uses
CA2635623C (en) 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
JP5825756B2 (ja) * 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ１９を標的とする最適化抗体
AU2007294575B2 (en) 2006-09-08 2013-06-27 Viela Bio, Inc. Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
US20110274697A1 (en) * 2009-01-16 2011-11-10 Cherry Teresa Thomas Novel uses
SG173654A1 (en) 2009-02-23 2011-09-29 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to cd19 and their uses
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CN102470172B (zh) * 2009-08-14 2014-09-24 罗切格利卡特公司 无岩藻糖基化cd20抗体与氟达拉滨和/或米托蒽醌的联合疗法
MX2012005163A (es) * 2009-11-06 2012-11-22 Infinity Pharmaceuticals Inc Formulaciones orales de un inhibidor de la ruta de hedgehog.

Also Published As

Publication number Publication date
JP6184952B2 (ja) 2017-08-23
HUE058350T2 (hu) 2022-07-28
KR20190107749A (ko) 2019-09-20
NZ617770A (en) 2016-01-29
US20200353077A1 (en) 2020-11-12
KR20140064873A (ko) 2014-05-28
ES2909722T3 (es) 2022-05-10
MX2013014933A (es) 2014-04-16
CN103732252B (zh) 2017-11-10
PT2744515T (pt) 2022-05-19
KR20200058583A (ko) 2020-05-27
WO2013024097A1 (en) 2013-02-21
RS63238B1 (sr) 2022-06-30
SI2744515T1 (sl) 2022-05-31
HRP20220228T1 (hr) 2022-05-13
DK2744515T3 (da) 2022-03-28
US20140255427A1 (en) 2014-09-11
KR102115203B1 (ko) 2020-05-28
CY1125122T1 (el) 2024-12-13
AU2012296907B2 (en) 2017-01-05
LT2744515T (lt) 2022-04-25
SMT202200159T1 (it) 2022-05-12
EP2744515A1 (en) 2014-06-25
RU2625222C2 (ru) 2017-07-12
RU2014103492A (ru) 2015-09-27
SG10201606785UA (en) 2016-10-28
PL2744515T3 (pl) 2022-05-30
JP2014525926A (ja) 2014-10-02
BR112013033919A2 (pt) 2017-12-19
IL230293B (en) 2019-01-31
CA2841875C (en) 2021-11-02
CA2841875A1 (en) 2013-02-21
CA3137321A1 (en) 2013-02-21
MX354479B (es) 2018-03-07
US20240366756A1 (en) 2024-11-07
CN103732252A (zh) 2014-04-16
EP4062936A1 (en) 2022-09-28
EP2744515B1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
US20240366756A1 (en) Combinations and uses thereof
JP2023058502A (ja) 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用
JP6114273B2 (ja) 抗−ｃｄ１９抗体とプリン類似体の併用治療
JP2025131697A (ja) 組み合わせおよびその使用
KR102500868B1 (ko) 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도
JP2014525926A5 (enExample)
JP2014525925A5 (enExample)
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
HK40081594A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard
BR112018003263B1 (pt) Combinação sinérgica
HK1247122B (en) Combinations and uses thereof
NZ617770B2 (en) Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: MORPHOSYS AG (DE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/08/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25A Requested transfer of rights approved

Owner name: INCYTE CORPORATION (US)